fore-8394
forebio therapeutics
['fore8394', 'fore bio']
fore biotherapeutics presents positive interim data from phase 1/2a trial evaluating fore8394 in patients with advanced tumors with activating braf alterations at esmo 2022 
Breaking news from Business Wire